The Myth of Mycotoxins and Mold Injury
In recent years, mold has been blamed for many symptoms or a constellation of symptoms. These symptoms are usually vague and subjective and difficult or impossible to measure or quantify. Moreover, there is no scientific evidence that mold has anything to do with these symptoms. In particular, the concept of toxic mold syndrome has permeated the public consciousness, and mycotoxins have falsely been associated with autoimmune diseases and a variety of other conditions. In fact, there is no evidence that the presence of mycotoxins in the air is enough to cause any disease known to man. Molds legitimately can cause allergies and can be a trigger for asthma. Certain specific molds such as Aspergillus can be a cause of hypersensitivity pneumonitis. In immunocompromised hosts, both dermatologic and systemic infections can result from various fungi and can be associated with significant morbidity or even mortality. However, the existence of toxic mold syndrome has been disproven, despite the numerous disreputable practices such as testing homes for mold spores, measuring “mycotoxins” in the urine, and testing patients for IgG to mold. In truth, none of these techniques have been validated, nor do they have any relevance to any clinical disease. All that these tests that are being performed by laboratories of disrepute does is to further propagate misinformation and inflict unnecessary and often exorbitant costs on patients desperate for a clinical diagnosis, right or wrong, for their constellation of maladies.
KeywordsMycotoxins Mold spores Allergic rhinitis Allergic fungal sinusitis Allergic bronchopulmonary aspergillosis Stachybotrys Toxic black mold
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
There is no funding so no ethical approval is required.
No informed consent is required.
- 1.Centers for Disease C, Prevention (1994) Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR Morb Mortal Wkly Rep 43(48):881–883Google Scholar
- 2.Centers for Disease C, Prevention (2000) Update: pulmonary hemorrhage/hemosiderosis among infants—Cleveland, Ohio, 1993–1996. MMWR Morb Mortal Wkly Rep 49(9):180–184Google Scholar
- 4.Brandt M, Brown C, Burkhart J, Burton N, Cox-Ganser J, Damon S et al (2006) Mold prevention strategies and possible health effects in the aftermath of hurricanes and major floods. MMWR Recomm Rep 55:RR–8):1-27Google Scholar
- 5.NIOSH alert: Preventing occupational respiratory disease from exposures caused by dampness in office buildings, schools and other nonindustrial buildings. In: US Department of Health and Human Services C, editor. Cincinnati, OH 2012Google Scholar
- 14.Polizzi V, Delmulle B, Adams A, Moretti A, Susca A, Picco AM, Rosseel Y, Kindt R', van Bocxlaer J, de Kimpe N, van Peteghem C, de Saeger S (2009) JEM spotlight: fungi, mycotoxins and microbial volatile organic compounds in mouldy interiors from water-damaged buildings. J Environ Monit 11(10):1849–1858CrossRefPubMedCentralGoogle Scholar
- 20.Kawamoto M, Page E, Centers for Disease C, Prevention (2015) Notes from the field: use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness—United States, 2014. MMWR Morb Mortal Wkly Rep 64(6):157–158Google Scholar
- 23.Health hazard evaluation report: evaluation of health concerns in a public middle school—Virginia, Cincinnati, OH. US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health 2010Google Scholar
- 28.Grimsley LF, Wildfire J, Lichtveld M, Kennedy S, El-Dahr JM, Chulada PC et al (2012) Few associations found between mold and other allergen concentrations in the home versus skin sensitivity from children with asthma after hurricane Katrina in the head-off environmental asthma in Louisiana study. Int J Pediatr 2012:427358CrossRefPubMedCentralGoogle Scholar
- 40.Kohn A, Chang C (2019) The relationship between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Clin Rev Allergy ImmunolGoogle Scholar